While the precise extent to which the charges and
pending trials toward the end of this year may increase these outside legal costs is unclear, we do have at least one clue.
[NIAID Director Anthony] Fauci says $ 56 million of the total would go
toward a larger efficacy
trial in Liberia, which would include both the NIAID / GSK [GlaxoSmithKline] vaccine and another made by NewLink Genetics of Ames, Iowa (
pending more data from ongoing safety
trials).»